Etigilimab

GSK and iTeos Therapeutics have discontinued development of belrestotug, their TIGIT-targeting immunotherapy, after it failed to significantly delay tumor progression in non-small cell lung cancer patients.

Combination therapies are being explored to improve immunotherapy efficacy in pMMR/MSS metastatic colorectal cancer (mCRC) patients, who do not typically respond well to single-agent immune checkpoint inhibitors.

Mereo BioPharma's setrusumab Phase 3 Orbit study for osteogenesis imperfecta is ongoing, with a second interim analysis expected in mid-2025.

The FDA granted Breakthrough Therapy Designation to setrusumab for reducing fracture risk in osteogenesis imperfecta (OI) types I, III, and IV, for patients aged 2 years and older.

Mereo BioPharma Group plc has announced an updated operating plan aimed at maximizing shareholder value by reducing headcount by 40% and significantly cutting expenses. The plan extends the company's cash runway into 2026 and focuses on advancing its core rare disease programs. Updates on lead programs include progress on setrusumab for Osteogenesis Imperfecta, alvelestat for Alpha-1 antitrypsin deficiency, and etigilimab in combination with nivolumab for cancer treatment.